Existing patient monitoring workflows often rely on nurses managing patients from centralised workstations, monitoring vitals and biomarkers at different intervals, and manually collecting vitals. This process can be inefficient, especially with limited workstations, multiple workflows, increased patient volumes, and nursing shortages.

By the first quarter of 2025, Singapore & US-based startup Respiree will team up with Roche to launch pilot programmes across Asia Pacific (APAC) that offer a simplified approach to patient monitoring by combining Roche's cobas pulse system with Respiree's vital sign monitoring. The solution is also expected in future to integrate machine learning models that predict clinical deterioration using historical data with risk scores at the bedside. 

The cobas pulse system, a point of care device, equipped with digital health applications based on the Android operating system allows for real-time administration and visualisation, eliminating the need for centralised workstations. Respiree's solution measures multiple biometrics, including pulse rate, oxygen saturation, respiratory rate, temperature, tidal depth, inhalation-to-exhalation ratios, and has the capability to input blood pressure measurements.

With the use of Respiree and cobas pulse solutions, healthcare professionals can register patients to Respiree's connected devices in real-time, monitor historical data and potential deterioration directly at the patient's bedside without needing to return to workstations or medical carts, as well as simultaneously measure vital signs and blood sugar. They can annotate clinical notes on the Respiree solution in the cobas pulse system.